Highly concentrated stable meloxicam solutions for needleless injection

Information

  • Patent Grant
  • 8920820
  • Patent Number
    8,920,820
  • Date Filed
    Wednesday, November 13, 2013
    11 years ago
  • Date Issued
    Tuesday, December 30, 2014
    9 years ago
Abstract
An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.
Description

The present invention relates to highly concentrated stable meloxicam solutions for intracutaneous or subcutaneous needleless injection for treating respiratory diseases and inflammation in mammals.


BACKGROUND OF THE INVENTION

Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide) is an active substance which belongs to the group of NSAIDs (non-steroidal-anti-inflammatory drugs). Meloxicam and the sodium and meglumine salt thereof (N-methyl-D-glucamine salt) are described in EP-A-0 002 482. EP-A-0 002 482 shows, inter alia, the example of a 0.2% injectable solution of meloxicam consisting of the meglumine salt of the active substance, sodium chloride and water.


EP-A-0 945 134 discloses the pH-dependent solubility characteristics of meloxicam and its salts, i.e. the sodium salt, the ammonium salt and the meglumine salt, in aqueous solution. According to this, meloxicam is an active substance which does not dissolve readily in water. The meloxicam salts, particularly the meglumine salt, exhibit improved solubility as the pH increases between 4 and 10, as shown in Table 1 of EP-0 945 134. However, up till now it has only been possible to produce stable, clear, aqueous solutions with a low concentration of meloxicam. In addition to the in situ formation of a meloxicam salt, e.g. meglumine salt, and the addition of solubilisers, these solutions were required to have a pH in the range of maximum possible solubility as well as being reasonably well tolerated and contain a high proportion of organic solvent. Attempts to produce formulations with the same or a similar recipe led to cloudiness of the solution, e.g. if the meloxicam concentrations were higher, e.g. 2%.


WO9959634 A1 describes an eye drop solution containing 0.5% meloxicam but makes no reference to possible meloxicam concentrations over 1%. A commercially available 0.5% meloxicam solution is used in small animals such as dogs, heifers and calves to treat respiratory diseases and inflammation, for example.


An active substance for needleless injection makes it possible for the animal keeper himself to administer a sterile solution to the animal. The requirements imposed on an active substance solution for needleless injection include inter alia small injectable volumes, the possibility of weight-related dosage and maximum possible flexibility in the number of actuation processes per treatment unit. Accordingly, injection volumes of 50 μl per actuation, for example, are technically feasible. For this purpose, as described in DE10010123 A1, a sterile solution may be transferred under aseptic conditions into a sterile cartridge which is then inserted in the metering system.


It has not hitherto been possible to treat large farm animals with a meloxicam solution that could be injected without a needle. The low concentration of active substance in the injectable solution did not allow an acceptable, well tolerated injection volume. The administration of meloxicam solutions by needlefree injection requires that the solution be free from particles, as solutions of this kind are subject to the same requirements as solutions for parenteral administration. In addition to intracutaneous and subcutaneous administration transcutaneous administration should also be taken into consideration, involving administering the substance directly into the blood vessels. This latter route is directly comparable with intravenous administration by injection through a syringe. The method of administration by needle-free injection has a relevant effect on bioavailability, which will be greater than with intracutaneous or subcutaneous administration, as transcutaneous absorption also takes place with needle-free injection. Organic solvents, solubilisers and water-soluble substances can only be used in certain concentrations for reasons of drug tolerance. The problem of the present invention is to produce particle-free highly concentrated meloxicam solutions which are stable over long periods, which are suitable for needleless injection.


DESCRIPTION OF THE INVENTION

Surprisingly, it has been found that highly concentrated meloxicam solutions with a content of active substance ranging from 35 to 100 mg/ml which contain, in addition to a meloxicam salt and certain excipients, another excipient selected from among citric acid, lecithin, gluconic acid, tartaric acid, phosphoric acid and EDTA or the salts thereof, may be produced so as to be particle-free and stable over long periods. The stability was achieved with an unexpectedly small amount of organic solubilisers. The formulation was found to be stable even when subjected to the process of final sterilisation.


This results in the solution to the problem according to the invention, as a formulation of a meloxicam solution which contains, in addition to a meloxicam salt, small concentrations of solubiliser, a preservative, a buffer substance for achieving the optimum pH range and another excipient.


The invention relates, as described in claim 1, to aqueous cyclodextrin-free solutions of meloxicam for needle-free intracutaneous or subcutaneous administration which contain a pharmacologically acceptable meloxicam salt of an organic or inorganic base in a highly concentrated solution with 35 to 100 mg/ml of meloxicam together with suitable excipients. Subclaims 2-14 describe advantageous further features of the invention.


The formulation according to the invention overcomes the problem arising from the prior art of providing a solution of the active substance meloxicam which is suitable for needleless injection, by permitting a high concentration of active substance in a particle-free solution which is stable over the long term, having the composition described hereinafter.


The formulation according to the invention may contain, as the meloxicam salt, the meglumine, sodium, potassium or ammonium salt, preferably the meloxicam meglumine salt.


The solubilisers used may be, for example polyethyleneglycols, polyoxyethylene-polyoxypropylene copolymers (e.g. poloxamer 188), glycofurol, arginine, lysine, castor oil, propyleneglycol, solketal, polysorbate, glycerol, sorbitol, mannitol, xylitol, polyvinylpyrrolidone, lecithin, cholesterol, 12-hydroxystearic acid-PEG660-ester, propyleneglycol monostearate, polyoxy-40-hydrogenated castor oil, polyoxyl-10-oleyl-ether, polyoxyl-20-cetostearylether and polyoxyl-40-stearate or a mixture of sorbitol, mannitol and xylitol, preferably polyethyleneglycols, polyoxyethylene-polyoxypropylene copolymers, glycofurol, polyvinylpyrrolidone, lecithin, cholesterol, 12-hydroxystearic acid-PEG660-esters, propyleneglycol monostearate, polyoxy-40-hydrogenated castor oil, polyoxyl-10-oleyl-ether, polyoxyl-20-cetostearylether and polyoxyl-40-stearate. Particularly preferred are polyethyleneglycols, glycofurol and polyoxyethylene-polyoxypropylene-copolymers, but especially polyethyleneglycols (e.g. Macrogol 300) and polyoxyethylene-polyoxypropylene copolymers (e.g. Poloxamer 188). The preservatives used may be, for example, ethanol, benzoic acid and the sodium or potassium salts thereof, sorbic acid and the sodium or potassium salts thereof, chlorobutanol, benzyl alcohol, phenylethanol, methyl, ethyl, propyl or butyl-p-hydroxybenzoates, phenol, m-cresol, p-chloro-m-cresol or benzalkonium chloride. Particularly preferred are ethanol, benzoic acid and the sodium or potassium salts thereof, sorbic acid and the sodium or potassium salts thereof, chlorobutanol, benzylalcohol, phenylethanol and methyl, ethyl, propyl or butyl p-hydroxybenzoates, but preferably ethanol, benzoic acid and the sodium or potassium salts thereof, sorbic acid and the sodium or potassium salts thereof, but especially ethanol.


The buffer system used to achieve a pH of between 8 and 10 may be, for example, glycine, a mixture of glycine and HCl, a mixture of glycine and sodium hydroxide solution, and the sodium and potassium salts thereof, a mixture of potassium hydrogen phthalate and hydrochloric acid, a mixture of potassium hydrogen phthalate and sodium hydroxide solution or a mixture of glutamic acid and glutamate. Glycine, a mixture of glycine and HCl and a mixture of glycine/sodium hydroxide solution, especially glycine, are particularly preferred.


Other suitable excipients are citric acid, lecithin, gluconic acid, tartaric acid, phosphoric acid and EDTA or the alkali metal salts thereof, preferably tartaric acid and EDTA or the alkali metal salts thereof, particularly disodium EDTA.


One embodiment of the invention contains, in addition to the meglumine or sodium salt of the meloxicam, polyethyleneglycols, glycofurol and/or polyoxyethylene-polyoxypropylene copolymers, but particularly polyethyleneglycols (e.g. Macrogol 300) and/or polyoxyethylene-polyoxypropylene copolymers (e.g. Poloxamer 188) as solubiliser, ethanol, benzoic acid and the sodium or potassium salts thereof or sorbic acid and the sodium or potassium salts thereof, but particularly ethanol, as preservative, and glycine, a mixture of glycine/HCl or a mixture of glycine/sodium hydroxide solution, but preferably glycine, as buffer and disodium EDTA as an additional excipient.


The formulation according to the invention may contain meloxicam in a concentration of 35-100 mg/ml, preferably 40-80 mg/ml, preferably 45-70 mg/ml, particularly preferably 50-60 mg/ml, especially 55 mg/ml.


The meglumine concentration may be between 30 and 50 mg/ml, preferably 35-45 mg/ml, preferably 38-42 mg/ml, especially about 40 mg/ml. The possible sodium, potassium and ammonium concentrations are calculated accordingly.


The concentration of the solubilisers may be in the range from 20-200 mg/ml, preferably 30-150 mg/ml, preferably 40-130 mg/ml, more preferably 50-120 mg/ml, especially 70-100 mg/ml.


The concentration of the preservative ethanol may be in the range from 100-200 mg/ml, preferably 120-180 mg/ml, more preferably about 150 mg/ml.


The concentration of the preservatives benzoic acid and the sodium or potassium salts thereof, sorbic acid and the sodium or potassium salts thereof, chlorobutanol, benzyl alcohol, phenylethanol, phenol, m-cresol and p-chloro-m-cresol may be in the range from 0.5-50 mg/ml, preferably 1-10 mg/ml, more preferably 3-5 mg/ml.


The concentration of the preservatives benzalkonium chloride, phenylmercury nitrate and methyl-, ethyl-, propyl- or butyl-p-hydroxybenzoates may be in the range from 0.01-4 mg/ml, preferably 0.02-3 mg/ml, more preferably 0.1-0.5 mg/ml.


The concentration of the buffer substances may be between 4 and 138 mg/ml, preferably between 5 and 20 mg/ml, more preferably between 8 and 10 mg/ml.


The concentration of the other excipients mentioned above, i.e. EDTA, citric acid, lecithin, gluconic acid, tartaric acid and phosphoric acid or the salts thereof may be in the range from 0.2-3 mg/ml, preferably 0.3-2.5 mg/ml, preferably 0.5-2 mg/ml, most preferably 0.6-1.5 mg/ml, and in particular 0.7-1.0 mg/ml.


Meglumine and meloxicam may be used in a molar ratio of between 9:8 and 12:8, preferably in a molar ratio of 11:8, but especially in a molar ratio of 10:8.


In the formulation according to the invention, meloxicam and the other excipient, particularly disodium EDTA, may be present in a weight ratio of between 100:1 and 35:1, preferably between 80:1 and 40:1, preferably between 70:1 and 45:1, more preferably between 60:1 and 50:1, most preferably between 58:1 and 52:1, in particular about 55:1.


The formulation according to the invention may have a shelf-life after opening of 28 days or more.


The shelf-life of the solution in the sealed original packaging may be 1 month or more, in particular between 1 month and 24 months, but at least between 1 month and 18 months, preferably between 1 month and 12 months, more preferably between 1 month and 9 months, most preferably between 1 month and 6 months, particularly between 1 month and 3 months.


The formulation according to the invention should have a pH of between 8 and 10, preferably between 8.5 and 9, more preferably a pH between 8.7 and 8.9, particularly 8.8.


The formulation according to the invention is suitable for treating pain, inflammation, fever, acute mastitis, diarrhoea, lameness, oncological indications, problems with the locomotor apparatus, and respiratory complaints in animals, preferably acute mastitis, diarrhoea, lameness, problems with the locomotor apparatus and respiratory complaints, especially acute mastitis, diarrhoea, lameness, problems with the locomotor apparatus and respiratory complaints, most preferably respiratory complaints and oncological indications. The treatment may be given in conjunction with antibiotic therapy.


The formulation according to the invention is suitable for treating animals, preferably mammals, more particularly domestic pets, working animals or farm animals.


The formulation according to the invention is suitable for treating animals, preferably animals up to 500 kg, particularly domestic pets from 1 kg upwards, more preferably from 2 to 70 kg, most preferably 5 to 60 kg, or large animals up to 750 kg, preferably 50 kg to 500 kg, most preferably 100 to 400 kg.


The dosage of the formulation according to the invention should correspond to 0.1 to 1.0 mg of active substance per kg of bodyweight, preferably 0.4 to 0.8 mg/kg of bodyweight, more preferably 0.5 to 0.7 mg/kg of bodyweight, particularly preferably 0.6 mg/kg of bodyweight.


The formulation according to the invention may be prepared using the methods of preparing aqueous liquid formulations known from the literature. For example, the appropriate excipients may be added to a meloxicam salt solution.


Various commercial materials for aqueous liquid formulations which will allow sealing under inert gas and/or final sterilisation by autoclaving in the finished container may be used as a packaging material for the formulation according to the invention. Such materials include for example ampoules or glass vials, particularly glass vials, e.g. 50 ml or 100 ml glass vials of glass Type I (according to Pharm. Eur/USP) in conjunction with rubber stoppers made of ethylenepropylenenorbornene terpolymer (EPDM) and aluminium caps. Vials made of plastics, particularly COC (Cyclic Olefin Copolymer), and other types of rubber stoppers are also suitable.


The meloxicam solutions according to the invention will now be illustrated by the following Example. Anyone skilled in the art will be aware that the Example serves only as an illustration and is not to be regarded as restrictive.







EXAMPLE

4% meloxicam solution















Ingredients:
g/100 ml


















Meloxicam
4.0



Meglumine
2.8



Macrogol 300*1
15.0



Poloxamer 188*2
5.0



Ethanol
15.6



Glycine
0.5



EDTA-Na
0.1



1M HCl
q.s. ad pH 8.8



1M NaOH
q.s. ad pH 8.8



Water for injections
ad 100 ml





*1obtainable from Brenntag, Plochingen, Germany


*2obtainable from C. H. Erbsloeh, Krefeld, Germany






For example, dogs may be treated by needle-free injection with a 4% meloxicam solution according to the invention in a metered volume of 50 μl per spray jet in a precise dosage related to body weight. A dog weighing 10 kg can be treated with a dose of 0.2 mg of meloxicam per kg of body weight with precisely one spray jet. Therapeutic accuracy is ensured in this case in steps of 10 kg.


Method of Preparation


4 g of meloxicam are dissolved in 50 ml of an aqueous meglumine solution (1.4 g/50 ml) at 90° C. The other excipients are added one after another to the solution according to the recipe given above. The pH is then adjusted to 8.8 using 1M hydrochloric acid and 1M sodium hydroxide solution. Water is added to the solution until a volume of 100 ml is obtained.

Claims
  • 1. An aqueous particle free highly concentrated meloxicam solution suitable for administration by needleless injection, comprising: 40 to 80 mg/ml meloxicam;meglumine in amount such that the meglumine and meloxicam are present in a molar ratio of between 9:8 and 12:8;disodium EDTA in an amount such that the weight ratio of meloxicam to disodium EDTA is between 100:1 and 35:1;a polyethylene glycol;a polyoxyethylene-polypropylene copolymer; andethanol;wherein the solution is free of cyclodextrin, the solution has a pH of between 8.5 and 9, and the solution has a shelf-life after opening of 28 days or more.
  • 2. The aqueous solution according to claim 1, wherein the meglumine and meloxicam are present in a molar ratio of 10:8.
  • 3. The aqueous solution according to claim 1, further comprising glycine.
  • 4. The aqueous solution according to claim 1, wherein the solution comprises meloxicam, meglumine, a polyethyleneglycol, a polyoxyethylene-polyoxypropylene copolymer, ethanol, glycine, disodium EDTA, and water suitable for injection.
  • 5. The aqueous solution according to claim 4, wherein the solution further comprises sodium hydroxide or hydrochloric acid.
  • 6. The aqueous solution according to claim 1, further comprising a buffer or a preservative.
  • 7. The aqueous solution according to claim 1, further comprising a solubilizer.
  • 8. The aqueous solution according to claim 1, wherein the solution has a long term shelf-life of 24 months or more in its original packaging.
  • 9. A sterile cartridge containing a solution according to claim 1.
Priority Claims (1)
Number Date Country Kind
101 61 077 Dec 2001 DE national
US Referenced Citations (101)
Number Name Date Kind
2795529 Alburn et al. Jun 1957 A
3288675 Newmark et al. Nov 1966 A
3849549 Dempski et al. Nov 1974 A
3931212 Satzinger et al. Jan 1976 A
3947576 Kuczkowski et al. Mar 1976 A
4233299 Trummlitz et al. Nov 1980 A
4482554 Gebhardt et al. Nov 1984 A
4628053 Fries Dec 1986 A
4748174 Veronesi May 1988 A
4794117 Corbiere Dec 1988 A
4835187 Reuter et al. May 1989 A
4942167 Chiesi et al. Jul 1990 A
5169847 Nagy nee Kricsfalussy et al. Dec 1992 A
5178878 Wehling et al. Jan 1993 A
5283065 Doyon et al. Feb 1994 A
5304561 Sarfarazi Apr 1994 A
5360611 Robertson et al. Nov 1994 A
5414011 Fu et al. May 1995 A
5489439 Bola Feb 1996 A
5654003 Fuisz et al. Aug 1997 A
5700816 Isakson et al. Dec 1997 A
5811446 Thomas Sep 1998 A
5824658 Falk et al. Oct 1998 A
5886030 Maniar Mar 1999 A
6046191 Hamley et al. Apr 2000 A
6071539 Robinson et al. Jun 2000 A
6090800 Unger et al. Jul 2000 A
6106862 Chen et al. Aug 2000 A
6136804 Nichtberger Oct 2000 A
6156349 Steinbach et al. Dec 2000 A
6166012 Muller et al. Dec 2000 A
6180136 Larson et al. Jan 2001 B1
6183779 Ouali et al. Feb 2001 B1
6184220 Turck et al. Feb 2001 B1
6187800 Suri et al. Feb 2001 B1
6221377 Meyer Apr 2001 B1
6284269 Struengmann et al. Sep 2001 B1
6495603 Miyake et al. Dec 2002 B1
6599529 Skinhøj et al. Jul 2003 B1
6605295 Bellmann et al. Aug 2003 B1
6630056 Thibierge et al. Oct 2003 B1
6669957 Laruelle et al. Dec 2003 B1
6682747 Turck et al. Jan 2004 B1
6869948 Bock et al. Mar 2005 B1
6986346 Hochrainer et al. Jan 2006 B2
7105512 Morizono et al. Sep 2006 B2
7969206 Ito Jun 2011 B2
20010055569 Davis et al. Dec 2001 A1
20020006440 Cherukuri Jan 2002 A1
20020016342 Scolnick et al. Feb 2002 A1
20020035107 Henke et al. Mar 2002 A1
20020058908 Zierenberg et al. May 2002 A1
20020068088 Gruber Jun 2002 A1
20020077328 Hassan et al. Jun 2002 A1
20020099049 Burch et al. Jul 2002 A1
20020106345 Uhrich et al. Aug 2002 A1
20020187187 Ohki et al. Dec 2002 A1
20030055051 Morizono et al. Mar 2003 A1
20030109701 Coppi et al. Jun 2003 A1
20030119825 Folger et al. Jun 2003 A1
20030199482 Seibert et al. Oct 2003 A1
20030220306 Simmons et al. Nov 2003 A1
20040001883 Matsui et al. Jan 2004 A1
20040015126 Zierenberg et al. Jan 2004 A1
20040024041 Selzer Feb 2004 A1
20040024042 Breyer Feb 2004 A1
20040037869 Cleverly et al. Feb 2004 A1
20040043992 Tolba et al. Mar 2004 A1
20040110747 Altman Jun 2004 A1
20040170687 Hurd et al. Sep 2004 A1
20040171611 Trummlitz et al. Sep 2004 A1
20040180092 Henke et al. Sep 2004 A1
20040198826 Baiker et al. Oct 2004 A1
20040204413 Faour et al. Oct 2004 A1
20040204472 Briggs et al. Oct 2004 A1
20040214753 Britten et al. Oct 2004 A1
20040229038 Cooper et al. Nov 2004 A1
20040234596 Ohki et al. Nov 2004 A1
20040253312 Sowden et al. Dec 2004 A1
20050038018 Kanbe et al. Feb 2005 A1
20050187212 Ohki et al. Aug 2005 A1
20050187213 Lang et al. Aug 2005 A1
20050197332 Altman Sep 2005 A1
20050244491 Ohki et al. Nov 2005 A1
20050245510 Friton et al. Nov 2005 A1
20050277634 Janott et al. Dec 2005 A1
20050288280 Friton et al. Dec 2005 A1
20060079516 Henke et al. Apr 2006 A1
20060160793 Altman Jul 2006 A1
20060217431 Daemmgen et al. Sep 2006 A1
20070077296 Folger et al. Apr 2007 A1
20070099907 Altman May 2007 A1
20080132493 Folger et al. Jun 2008 A1
20080234380 Shapiro Sep 2008 A1
20080280840 Lang et al. Nov 2008 A1
20110083985 Folger et al. Apr 2011 A1
20110275618 Folger et al. Nov 2011 A1
20120077764 Freehauf et al. Mar 2012 A1
20130178467 Henke et al. Jul 2013 A1
20140066440 Folger et al. Mar 2014 A1
20140113893 Folger et al. Apr 2014 A1
Foreign Referenced Citations (103)
Number Date Country
673675 Nov 1996 AU
1102802 Jun 1981 CA
2164100 Jan 1995 CA
2166204 Jan 1995 CA
2326517 Oct 1999 CA
2404360 Sep 2001 CA
2414063 Dec 2001 CA
2469588 Jun 2003 CA
2503396 May 2004 CA
3434707 Apr 1985 DE
3700172 Jul 1987 DE
4217971 Oct 1993 DE
19729879 Jan 1999 DE
10010123 Sep 2001 DE
10024752 Nov 2001 DE
10032132 Jan 2002 DE
10300323 Oct 2004 DE
0002482 Jun 1979 EP
0034432 Aug 1981 EP
0093999 Nov 1983 EP
0177870 Apr 1986 EP
0179430 Apr 1986 EP
0306984 Mar 1989 EP
0360246 Mar 1990 EP
0390071 Oct 1990 EP
0422681 Apr 1991 EP
0465235 Jan 1992 EP
0560329 Sep 1993 EP
0945134 Sep 1999 EP
1082966 Mar 2001 EP
1190714 Mar 2002 EP
1568369 Aug 2005 EP
2065846 Feb 1995 ES
2159564 Oct 2001 ES
2437838 Apr 1980 FR
2455875 Jun 2009 GB
1251650 May 1995 IT
47007352 Mar 1972 JP
1299230 Dec 1989 JP
11139971 May 1999 JP
2001170083 Jun 2001 JP
2001172183 Jun 2001 JP
2003535902 Dec 2003 JP
3550782 Aug 2004 JP
4018022 Dec 2007 JP
04321624 Aug 2009 JP
9301814 Feb 1993 WO
9400420 Jan 1994 WO
9509639 Apr 1995 WO
9517178 Jun 1995 WO
9518604 Jul 1995 WO
9603387 Feb 1996 WO
9603388 Feb 1996 WO
9610999 Apr 1996 WO
9611192 Apr 1996 WO
9641625 Dec 1996 WO
9703655 Feb 1997 WO
9703667 Feb 1997 WO
9717978 May 1997 WO
9717989 May 1997 WO
9729776 Aug 1997 WO
9731631 Sep 1997 WO
9817250 Apr 1998 WO
9909988 Mar 1999 WO
9912524 Mar 1999 WO
9927906 Jun 1999 WO
9949845 Oct 1999 WO
9949867 Oct 1999 WO
9959634 Nov 1999 WO
0015195 Mar 2000 WO
0108689 Feb 2001 WO
0137838 May 2001 WO
WO 0137838 May 2001 WO
0152897 Jul 2001 WO
0164268 Sep 2001 WO
0187343 Nov 2001 WO
0197813 Dec 2001 WO
02085331 Oct 2002 WO
03049733 Jun 2003 WO
03082297 Oct 2003 WO
03097066 Nov 2003 WO
2004004776 Jan 2004 WO
2004026116 Apr 2004 WO
2004026313 Apr 2004 WO
2004037264 May 2004 WO
2004089379 Oct 2004 WO
2004103283 Dec 2004 WO
2005002542 Jan 2005 WO
2005004915 Jan 2005 WO
2005079806 Sep 2005 WO
2005105101 Nov 2005 WO
2005115386 Dec 2005 WO
2006000306 Jan 2006 WO
2006100213 Sep 2006 WO
2007039417 Apr 2007 WO
2007087214 Aug 2007 WO
2007135505 Nov 2007 WO
2008113149 Sep 2008 WO
2008152122 Dec 2008 WO
2009049304 Apr 2009 WO
2011046853 Apr 2011 WO
2011107498 Sep 2011 WO
2011138197 Nov 2011 WO
Non-Patent Literature Citations (82)
Entry
Winfield, Pharmaceutical Practice, Ophthalmic Products—Chelating agents, Churchill Livingstone, 2004, 268.
“Committee for Veterinary Medicinal Products—Meloxicam (Extension to PIGS)—Summary Report (5)”. The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines and Information Technology, Dec. 2000, pp. 1-3.
“Metacam (R) 05 mg/ml oral suspension for cats.” Boehringer Ingelheim Datasheet, Web site: http://www.vetgb.com/vetgb—pdfs/metacamc—7a5c—vetgb.pdf> Accessed on Jun. 8, 2010.
“Metacam(R)” FDA Animal & Veterinary Drug Labels, Web site: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050397.pdf> Accessed Jun. 8, 2010.
“METACAM—Community register of veterinary medicinal products” accessed online at http://pharmacos.eudra.org/F2/register/v004.htm, 2005.
“Types of Solutions”. University of Wisconsin, Stevens Point, Feb. 1, 2001, accessed at http://www.uwsp.edu/chemistry/tzamis/chem106pdfs/solutionexamples.pdf, Google date sheet included, 2 pages.
Abstract in English for IT1251650, 1995.
Abstract in English of DE10024752, 2001.
Abstract in English of DE3434707, 1985.
Abstract in English of ES2065846, 1995.
Abstract in English of FR2437838, 1980.
Abstract in English of JP02906528, 1999.
Abstract in English of JP11139971, 1999.
Abstract in English of JP2001170083, 2001.
Abstract in English of JP3550782, 2004.
Abstract in English of JP4018022, 2007.
Abstract in English of JP47007352, 1972.
Abstract in English of WO199301814, 1993.
Altman et al., “Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation: The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study”. Circulation, vol. 106, 2002, pp. 191-195.
Ansel et al., “Pharmaceutical Dosage Forms and Drug Delivery Systems”. Seventh Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1999, pp. 77-87.
Bednarek et al., “Effect of steroidal and non-steroidal anti-imflammatory drugs in combination with long-acting oxytetracycline on non-specific immunity of calves suffering from enzootic bronchopneumonia”. Veterinary Microbiology, vol. 96, 2003, pp. 53-67.
Bednarek et al., “The effect of steroidal and non-steroidal anti-inflammatory drugs on the cellular immunity of calves with experimentally-induced local lung inflammation”. Veterinary Immunology and Immunopathology, vol. 71, 1999, pp. 1-15.
Boehringer Ingelheim; Metacam (Meloxicam) Now Approved for Pigs and Mastitis in Dairy Cows; May 2003 Press Release; pp. 1-2.
Bunji, Kouho, “Tissue Damage Due to Infections”. Drug Injection Handbook, Fundamentals of Blending Variation for Injection Drugs, Nanzando Co. Ltd., Tokyo, 1976, p. 5.
Cho et al., “In vitro effects of Actinobacillus pleuropneumoniae on inducible nitric oxide synthase and cyclooxygenase-2 in porcine alveolar macrophages”. American Journal of Veterinary Research, vol. 64, No. 12, Dec. 2003, pp. 1514-1518.
Clarke et al., “Feline osteoarthritis: a prospective study of 28 cases”. Journal of Small Animal Practice, vol. 47, 2006, pp. 439-445.
D'Yakov et al., “Long term use of Tamsulosin (omnic®) in Patients with Chronic Prostatitis”. Urologiia, vol. 5, 2002, pp. 10-12.
Del Tacca et al., “Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug”. Clinical Drug Investigation, vol. 22, No. 12, 2002, pp. 799-818.
Dellabella et al., “Conservative Managment of Juxtavesical Calculi with Tamsulosin”. European Urology Supplements, vol. 2, No. 1, 2003, p. 81.
DOW Chemicals Brochure, entitled “Using METHOCEL cellulose ethers for controlled release of drugs in hyrophilic matrix systems.” Publication Jul. 2000, Form No. 198-02075-700 AMS, pp. 1-36.
Dunn et al., “Tamsulosin: A Review of its Pharmacology and Therapeutic Efficacy in the Management of Lower Urinary Tract Symptoms”. Drugs & Aging, vol. 19, No. 2, 2002, pp. 132-161.
Engelhardt et al., “Meloxicam: Influence on Arachidonic Acid Metabolism”. Biochemical Pharmacology, vol. 51, 1996, pp. 21-28.
Ettmayer et al., “Lessons Learned from Marketed and Investigational Prodrugs”. Journal of Medicinal Chemistry, vol. 47, No. 10, May 2004, pp. 2393-2404.
European Search Report for EP10155400 dated Jun. 9, 2010.
European Search Report for EP10162015 dated Aug. 30, 2010.
Farkouh et al., “Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial”. Lancet, vol. 364, Aug. 2004, pp. 675-684.
Fitzgerald et al., “COX-2 inhibitors and the cardiovascular system”. Clinical and Experimental Rheumatology, vol. 19, No. 6, Supp. 25, Nov. 2001, pp. S31-S36.
Fitzpatrick et al., “Recognising and Controlling Pain and Inflammation in Mastitis”. Proceedings of the British Mastitis Conference, Axient/Institute for Animal Health, Milk Development Council/Novartis Animal Health, 1998, pp. 36-44.
Gerritsen et al., “Prostaglandin Synthesis and Release from Cultured Human Trabecular-meshwork Cells and Scleral Fibroblasts”. Experimental Eye Research, vol. 43, No. 6, 1986, pp. 1089-1102.
Giuliani et al., “Role of Antithrombotic Therapy in Cardiac Disease”. Mayo Clinic Practice of Cardiology, Third Edition, Mosby, St. Louis, MO, 1996, pp. 1116-1121.
Gollackner et al., “Increased apoptosis of hepatocyctes in vascular occulusion after orthotopic liver transplantation”. Transplant International, vol. 13, No. 1, 2000, pp. 49-53.
Gruet et al., “Bovine mastitis and intramammary drug delivery: review and perspectives”. Advanced Drug Delivery Reviews, vol. 50, 2001, pp. 245-259.
Gunew et al., “Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats”. Journal of Feline Medicine and Surgery, vol. 10, 2008, pp. 235-241.
Guth et al., “Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects”. British Journal of Clinical Pharmacology, vol. 58, No. 1, Jul. 2004, pp. 40-51.
Hawkey et al., “Gastrointestinal Tolerability of Meloxicam Compared to Diclofenac in Osteoarthritis Patients”. British Journal of Rheumatology, vol. 37, No. 9, 1998, pp. 937-945.
Herbort et al., “Anti-inflammatory Effect of Topical Diclofenac After Argon Laser Trabeculoplasty: Preliminary Results of a Placebo Controlled Study”. Klin. Monatsbl. Augenheik, vol. 200, No. 5, May 1992, pp. 358-361.
Hirsch et al, “Investigation on the efficacy of meloxicam in sows with mastitis-metritis-agalactia syndrome”. Journal of Veterinary Pharmacology and Therapeutics, vol. 26, 2003, pp. 355-360.
Hydrated Silica Webpage; http://science.kosmix.com/topic/hydrated—silica; Kosmix Corporation, Apr. 21, 2011, pp. 1-14.
International Search Report for PCT/EP2002/013983 mailed Apr. 23, 2003.
Jain et al., “Antiplatelet therapy in acute coronary syndromes without persistent ST-segment elevation”. Cardiovascular Drugs and Therapy, vol. 15, No. 5, Sep. 2001, pp. 423-436. [Abstract Only].
Kimura et al., “Effect of cilostazol on platelet agrregation and experimental thrombosis”. Arzneimittel-Forschung, vol. 35, No. 7A, 1985, pp. 1144-1149. [Abstract Only].
Kumar et al., “Comparative Studies on Effect of Some Hydrophilic Polymers on the Dissolution Rate of a Poorly Water Soluble Drug, Meloxicam”. Indian Drugs, vol. 39, No. 6, Apr. 2002, pp. 323-329.
Li et al., “Degradation mechanism and kinetic studies of a novel anticancer agent, AG2034”. International Journal of Pharmaceutics, vol. 167, 1998, pp. 49-56.
Lieberman et al., “Tablet Formulation and Design” in Pharmaceutical Dosage Forms: Tablets, vol. 1, Second Edition, Marcel Dekker, Inc., New York, New York, 1989, pp. 105-108.
Luger et al., “Structure and physicochemical properties of meloxicam, a new NSAID”. European Journal of Pharmaceutical Sciences, vol. 5, 1996, pp. 175-187.
Macdonald Campus of McGill University, “Mastitis in Dairy Cows”, published online, Jul. 2003, pp. 1-12.
Masferrer et al., “Cyclooxygenase-2 Inhibitors: A New Approach to the Therapy of Ocular Inflammation”. Survey of Ophthalmology, vol. 41, Supp. 2, Feb. 1997, pp. S35-S40.
McDonald et al., “Calpain inhibitor I reduces the activation of nuclear factor-KappaB and Organ Injury/Dysfunction in Hemorrhagic Shock”. The FASEB Journal, vol. 15, Jan. 2001, pp. 171-186.
Noble et al., “Meloxicam”. Drugs, vol. 51, No. 3, Mar. 1996, pp. 424-430.
Parikh et al., Binders and Solvents, Chapter 4, Handbook of Pharmaceutical Granulation Technology, First Edition, Marcel Dekker,1997, pp. 59-67.
Pharma Projects, Dialog File 928, Accession Nr. 0021312, Diclofenac, InSite Vision, 1996, 5 pages.
Pharmaceutical Excipent Encyclopedia, Yakuji Nippo Ltd., Tokyo, 1994, pp. 2-5.
Physicians' Desk Reference, 55th Edition, Medical Economics Company, Inc., 2001, pp. 981-984 and pp. 1404-1406.
Rantanen et al., “Process Analysis of Fluidized Bed Granulation”. AAPS PharmsciTech, vol. 2, No. 4, Article 21, 2001, 8 pages.
Remington: The Science and Practice of Pharmacy, 19th Edition, vol. II, Mack Publishing Company, Easton, Pennsylvania, 1995, p. 1646.
Robson et al., “Intrinsic acute renal failure (ARF) associated with non-steroidal anti-inflammatory drug (NSAId) use in juvenile cats undergoing routine desexing-16 cases 1998-2005”. May 2006, Journal of Veterinary Internal Medicine, vol. 20, No. 3, Abst. 109, p. 740.
Rudnic et al., “Oral Solid Dosage Forms”.,Gennaro, Editior, Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, PA, 1990, pp. 1633-1645 and pp. 1654-1655.
Saha et al., “Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers”. European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, No. 3, 2000, pp. 403-411, Abstract accessed at http://cat.inist.fr/?aModele=afficheN&cpsidt=798854, accessed on Aug. 13, 2010, 3 pages.
Schneeweis et al., “In Vivo and In Vitro Diclofenac Sodium Evaluation After Rectal Application of Soft Gelatine Capsules Enabling Application Induced Transformation (AIT) into a Seminsolid System of Liquid Crystals (SSLC) for Controlled Release”. Pharmaceutical Research, vol. 14, No. 12, Dec. 1997, pp. 1726-1729.
Sciencelab.com, “Lactose, Monohydrate, Spray-Dried Powder, NF”. Accessed at http://www.epoxy-paint.net/page/.S/PVAR/10419/SLL1453, Feb. 29, 2008, 2 pages.
Snyder et al., “Corticosteroid Treatment and Trabecular Meshwork Proteases in Cell and Organ Culture Supernatants”. Experimental Eye Research, vol. 57, No. 4, 1993, pp. 461-468.
Sorbera et al., “Lumiracoxib Antiarthritic, COX-2 Inhibitor”. Drugs of the Future, vol. 27, No. 8, Aug. 2002, pp. 740-747.
Stei et al., “Local Tissue Tolerability of Meloxicam, a New NSAID: Indications for Parental, Dermal and Mucosal Administration”. British Journal of Rheumatology, vol. 35, Supp. 1, 1996, pp. 44-50.
Straus et al., “New Evidence for Stroke Prevention: Clinical Applications”. The Journal of the American Medical Association, vol. 288, No. 11, Sep. 2002, pp. 1396-1398.
Straus et al., “New Evidence for Stroke Prevention: Scientific Review”. The Journal of the American Medical Association, vol. 288, No. 11, Sep. 2002, pp. 1388-1395.
Sunose et al., “The Effect of Cyclooxygenase 2 Inhibitor, FK3311, on Ischemia-Reperfusion Injury in Canine Lung Transplantation”. Journal of Heart and Lung Transplantation, vol. 19, No. 1, Jan. 2000, p. 40.
Turck al., “Clinical Pharmacokinetics of Meloxicam”. Arzneimittel-Forschung, vol. 47, No. 3, 1997, pp. 253-258.
Tunuguntla et al., “Management of Prostatitis”. Prostate Cancer and Prostatic Diseases, vol. 5, No. 3, 2002, pp. 172-179.
Vippagunta et al., “Crystalline solids”. Advanced Drug Delivery Reviews, vol. 48, 2001, pp. 3-26.
Wagenlehner et al., “Therapy of Prostatitis Syndrome”. Der Urologe [A], vol. 40, No. 1, 2001, pp. 24-28. [English Abstract at p. 25].
Nell et al., “Comparison of vedaprofen and meloxicam in dogs with muskuloskeletal pain and inflammation”. Journal of Small Animal Practice, vol. 43, No. 5, May 2002, pp. 208-212 [Accessed at http://www.ncbi.nlm.nih.gov/pubmed/12038853 on Sep. 27, 2013]. Abstract Only, 1 page.
Chemical Abstracts, vol. 118, No. 18, Abstract No. 175803, Columbus, OHion, US May 1993 & JP-A-04 321 624 (Hisamitsu Pharm.Co.Inc., JP), Nov. 11, 1992, 1 page.
Related Publications (1)
Number Date Country
20140113893 A1 Apr 2014 US
Continuations (2)
Number Date Country
Parent 11845675 Aug 2007 US
Child 14078953 US
Parent 10314586 Dec 2002 US
Child 11845675 US